about
Historical overview of biologic response modifiers.Engineered human vaccines.Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines.Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Active specific immunotherapy in malignant melanoma.
@en
type
label
Active specific immunotherapy in malignant melanoma.
@en
prefLabel
Active specific immunotherapy in malignant melanoma.
@en
P2093
P356
P1476
Active specific immunotherapy in malignant melanoma.
@en
P2093
Famatiga E
P304
P356
10.1002/SSU.2980050608
P577
1989-01-01T00:00:00Z